Brigham and Women's Hospital at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Brigham and Women's Hospital takes part in 11 sessions at CTAD 2026 in Boston, its home city. Its program combines prevention trial design with laboratory work on anti-amyloid antibodies and tau. Its work includes the PrevenTRON trial of trontinemab in cognitively unimpaired people, digital learning curves for early detection and complement activation by anti-amyloid antibodies.
| Organization | CTAD 2026 Attendance |
|---|---|
Brigham and Women's Hospital Boston, Massachusetts | |
Harvard teaching hospital whose Center for Alzheimer Research and Treatment leads prevention trials such as A4 and AHEAD. | Session Mon Nov 16 3:15pm–3:25pm Talk Tue Nov 17 9:10am–9:35am Talk Tue Nov 17 11:05am–11:45am Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Talk Wed Nov 18 9:55am Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm |
Instantly find 20 buyers from Brigham and Women's Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction